Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges

Novo Nordisk A/S TodayNVONovo Nordisk A/S$124.61 +0.91 (+0.74$86.96▼$148.15Dividend Yield0.58$145.17Add to WatchlistNovo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result. This included firms like Eli Lilly NYSE: LLY and Structure Therapeutics NASDAQ: GPCR.The drug in question was monlunabant. Although not a GLP-1 tre ...